# Sun Pharma Advanced Research Company (NSE: SPARC) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SPARC · Pivot · prices to 22 Oct 2026

Sun Pharma Advanced Research Company (NSE: SPARC) closed at ₹176.82 on 22 Oct 2026, down 1.22% on the day. With a market capitalisation of ₹5,738 Cr, it ranks 736th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 3.7× trailing earnings, against a return on equity of 116.0% in FY26. Over the past year the share price has risen 35.4%. Its 52-week range is ₹108.00 (23 Mar 2026) to ₹289.00 (8 Jul 2026); the last close is 38.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹13 Cr (−51.5% year on year) and net profit ₹1,761 Cr, on a consolidated basis. Promoters held 65.67% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹176.82 |
| Market cap | ₹5,738 Cr |
| P/E (trailing) | 3.7 |
| ROE | 116.0% (FY26) |
| ROCE | 112.9% (FY26) |
| Debt to equity | 0.42 |
| 52-week high | ₹289.00 (8 Jul 2026) |
| 52-week low | ₹108.00 (23 Mar 2026) |
| 1-year return | +35.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹13 Cr | −51.5% | ₹1,761 Cr | — | ₹54.27 |
| Q3 FY26 | ₹8 Cr | −43.3% | −₹80 Cr | — | −₹2.48 |
| Q2 FY26 | ₹8 Cr | −38.9% | −₹76 Cr | — | −₹2.34 |
| Q1 FY26 | ₹10 Cr | −42.7% | −₹52 Cr | — | −₹1.60 |
| Q4 FY25 | ₹27 Cr | +64.2% | −₹60 Cr | — | −₹1.84 |
| Q3 FY25 | ₹15 Cr | +7.6% | −₹80 Cr | — | −₹2.45 |
| Q2 FY25 | ₹13 Cr | −39.3% | −₹107 Cr | — | −₹3.31 |
| Q1 FY25 | ₹17 Cr | −29.8% | −₹96 Cr | — | −₹2.96 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹72 Cr | −₹343 Cr |
| FY24 | ₹76 Cr | −₹387 Cr |
| FY23 | ₹239 Cr | −₹223 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 65.67%
- Foreign institutions: 3.90%
- Domestic institutions: 0.09%
- Non-institutions: 30.33%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Kovai Medical Center & Hospital](https://app.pivotnow.in/stock/KOVAI) | ₹5,738.00 | ₹6,279 Cr | 25.7 | — |
| [Nephrocare Health Services](https://app.pivotnow.in/stock/NEPHROPLUS) | ₹599.90 | ₹6,019 Cr | 74.1 | — |
| [Senores Pharmaceuticals](https://app.pivotnow.in/stock/SENORES) | ₹1,233.30 | ₹5,680 Cr | 46.7 | — |
| [Innova Captab](https://app.pivotnow.in/stock/INNOVACAP) | ₹983.60 | ₹5,629 Cr | 40 | — |
| [FDC](https://app.pivotnow.in/stock/FDC) | ₹339.20 | ₹5,523 Cr | — | — |
| [IOL Chemicals and Pharmaceuticals](https://app.pivotnow.in/stock/IOLCP) | ₹173.27 | ₹5,086 Cr | 36.9 | — |

## Questions and answers

### What is the share price of Sun Pharma Advanced Research Company today?

Sun Pharma Advanced Research Company (NSE: SPARC) last closed at ₹176.82 on 22 Oct 2026. Its 52-week high is ₹289.00 and its 52-week low is ₹108.00.

### What is the market cap of Sun Pharma Advanced Research Company?

Sun Pharma Advanced Research Company's market capitalisation is ₹5,738 Cr (₹5,738 Cr) at the 22 Oct 2026 close, ranking 736th among the NSE companies Pivot tracks.

### What is the P/E ratio of Sun Pharma Advanced Research Company?

Sun Pharma Advanced Research Company trades at a trailing P/E of 3.7. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 40.

### What is the ROE and ROCE of Sun Pharma Advanced Research Company?

Return on equity was 116.0% in FY26 and return on capital employed was 112.9% in FY26 (consolidated figures).

### Is Sun Pharma Advanced Research Company a debt-free company?

No. Sun Pharma Advanced Research Company's debt-to-equity ratio was 0.42 in FY26, with total debt of ₹0 Cr.

### What were Sun Pharma Advanced Research Company's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Sun Pharma Advanced Research Company reported revenue of ₹13 Cr, −51.5% year on year, and net profit of ₹1,761 Cr.

### How has Sun Pharma Advanced Research Company stock performed over the last year?

Sun Pharma Advanced Research Company's share price has risen 35.4% over the past year, −17.3% over three months and −10.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Sun Pharma Advanced Research Company?

As of 30 Jun 2026: promoters 65.67%, foreign institutions 3.90%, domestic institutions 0.09%, non-institutions 30.33%.

### Who are Sun Pharma Advanced Research Company's competitors?

The listed Pharma & Healthcare companies closest to Sun Pharma Advanced Research Company by market cap are Kovai Medical Center & Hospital, Nephrocare Health Services, Senores Pharmaceuticals, Innova Captab, FDC and IOL Chemicals and Pharmaceuticals.

### Is Sun Pharma Advanced Research Company a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Sun Pharma Advanced Research Company's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SPARC against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.